Omar Siti Z, Qvist Rajes, Khaing Si L, Muniandy Sekaran, Bhalla Sunil
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
J Obstet Gynaecol Res. 2008 Apr;34(2):174-8. doi: 10.1111/j.1447-0756.2008.00755.x.
The aim of the present study was to determine the existence or prevalence of thrombophilic markers such as Factor V Leiden, prothrombin G20210A, protein S, protein C, activated protein C and anti-thrombin in pre-eclampsia and pregnancy-induced hypertensive patients.
Blood samples were collected from a total number of 124 women at the maternity unit, University of Malaya Medical Center. These included 49 patients with pre-eclampsia, 63 patients with pregnancy-induced hypertension and 12 normal pregnant women. DNA was extracted from the blood samples. Factor V Leiden (Taq I) and prothrombin G20210A (Hind III) genotyping was done on polymerase chain reaction-restriction fragment length polymorphism. Anti-thrombin activity and the concentrations of protein C, protein S and activated protein C were measured using the IL Coagulation System (Hemosil).
Of the 124 subjects, one pre-eclampsia patient was homozygous for Factor V Leiden mutation but prothrombin G20210A mutation was not present in any of the subjects. The subject with Factor V Leiden mutation also had a low activated protein C resistance and a low protein S concentration.
Factor V Leiden mutation is present in the Asian population and may very well serve as one of the genetic factors responsible for pre-eclampsia and other adverse pregnancy outcomes.
本研究旨在确定血栓形成倾向标志物,如凝血因子V莱顿突变、凝血酶原G20210A突变、蛋白S、蛋白C、活化蛋白C及抗凝血酶在子痫前期和妊娠高血压患者中的存在情况或流行程度。
从马来亚大学医学中心妇产科的124名女性中采集血样。其中包括49例子痫前期患者、63例妊娠高血压患者和12例正常孕妇。从血样中提取DNA。采用聚合酶链反应-限制性片段长度多态性方法进行凝血因子V莱顿(Taq I)和凝血酶原G20210A(Hind III)基因分型。使用IL凝血系统(Hemosil)检测抗凝血酶活性以及蛋白C、蛋白S和活化蛋白C的浓度。
在124名受试者中,1例子痫前期患者为凝血因子V莱顿突变纯合子,但所有受试者均未检测到凝血酶原G20210A突变。具有凝血因子V莱顿突变的受试者同时具有低活化蛋白C抵抗和低蛋白S浓度。
凝血因子V莱顿突变存在于亚洲人群中,很可能是子痫前期和其他不良妊娠结局的遗传因素之一。